About Editas Medicine Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.editasmedicine.com/
Frequently Asked Questions
What is the 52-week range for EDIT?
The 52-week high is $4.537 and the 52-week low is $1.66.
What is the P/E ratio for EDIT?
The P/E ratio data is currently unavailable.
What is the dividend yield for EDIT?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -196.63%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -157.32%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 7.33.
Analyst Recommendation Trends
Wall Street analyst consensus for EDIT over the last few months:
Latest EDIT News
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress
Beam Therapeutics (BEAM) stock analysis: BEAM-302 gene-editing upside for 2028â2029, cash runway/dilution risks, valuation vs peersâread now.
Prime: A Buy Due To BLA Filing H1 '27 And Continued PM647 Advancement
Prime Medicine, Inc. maintains a Buy rating, supported by an advancing prime editing pipeline and multiple upcoming clinical catalysts. Click for a PRME update.
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively.
Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls
Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon
CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader market, but the numbers tell a complicated story.
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.
This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Analysts upgraded Microsoft, Graphic Packaging, Editas Medicine and Lakefront Biotherapeutics, with mixed price-target changes.
Guggenheim Upgrades Editas Medicine to Buy, Announces $5 Price Target
Guggenheim analyst Debjit Chattopadhyay upgrades Editas Medicine (NASDAQ:EDIT) from Neutral to Buy and announces $5 price target.
Why Veea Shares Are Trading Higher By 58%; Here Are 20 Stocks Moving Premarket
Veea shares surged 58% premarket on a NovaGen merger plan and $10M GeoNova investment, while other stocks posted notable gains and losses.
Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy
Editas Medicine (NASDAQ:EDIT) outlined its strategy as an in vivo gene-editing company and said it remains on track to dose patients this year in a clinical study of its lead program, EDIT-401, for lowering LDL cholesterol. Speaking at the Cantor Healthcare Conference, President and Chief Executive
Editas Medicine Reports Inducement Grants to New Chief Medical Officer
CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the grant of an inducement award to the Company’s newly appointed Chief Medical Officer, Daniel Ory, M.D. In connection with Dr. Ory’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Dr. Ory as an inducement material to Dr. Ory entering into employment with Editas
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401
Editas Medicine (NASDAQ:EDIT) is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia, Chief Executive Officer Gilmore O’Neill said during a Wells Fargo discussion. O’Ne
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
Dan Ory, M.D. Editas Medicine today announced the appointment of Dan Ory, M.D., as Chief Medical Officer, effective today. Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as Editas advances EDIT-401 toward clinical development CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focu
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-08 | Ory Daniel Scott | +950,000 | - | - |
| 2026-09-03 | Parison Amy | -453 | $3.0372 | $1,376 |
| 2026-09-03 | Burkly Linda | -709 | $3.0372 | $2,153 |
| 2026-09-03 | O'Neill Gilmore Neil | -5,124 | $3.0372 | $15,563 |
| 2026-08-06 | Ellinor Patrick Thomas II | +103,400 | - | - |
| 2026-08-03 | Parison Amy | -678 | $2.58 | $1,749 |
| 2026-07-28 | Burkly Linda | -4,928 | $2.67 | $13,158 |
| 2026-06-17 | Connaughton Bernadette | +51,700 | - | - |
| 2026-06-17 | Scadden David | +51,700 | - | - |
| 2026-06-17 | Levy Elliott M. | +51,700 | - | - |
| 2026-06-17 | Hopfield Jessica | +51,700 | - | - |
| 2026-06-17 | Hirsch Andrew | +51,700 | - | - |
| 2026-06-03 | Parison Amy | -464 | $2.701 | $1,253 |
| 2026-06-03 | O'Neill Gilmore Neil | -15,380 | $2.7011 | $41,543 |
| 2026-06-03 | Burkly Linda | -731 | $2.7011 | $1,975 |
| 2026-03-12 | O'Neill Gilmore Neil | +1,015,200 | - | - |
| 2026-03-12 | Parison Amy | +292,856 | - | - |
| 2026-03-12 | Burkly Linda | +292,856 | - | - |
| 2026-03-03 | O'Neill Gilmore Neil | -5,394 | $2.0197 | $10,894 |
| 2026-03-03 | Parison Amy | -474 | $2.02 | $957 |
| 2026-03-03 | Burkly Linda | -749 | $2.0196 | $1,513 |
| 2025-12-03 | Burkly Linda | -713 | $2.1531 | $1,535 |
| 2025-12-03 | O'Neill Gilmore Neil | -5,603 | $2.1531 | $12,064 |
| 2025-12-03 | Parison Amy | -461 | $2.1531 | $993 |